CEO AlzeCure Pharma представит стратегию развития компании на конференции в Стокгольме

Генеральный директор шведской биотехнологической компании AlzeCure Pharma Мартин Йёнссон выступит с презентацией на ежегодной конференции Pareto Securities 2 сентября. В ходе мероприятия будут обсуждены последние достижения в разработке препаратов для лечения болезни Альцгеймера и боли, а также планы сотрудничества с Eli Lilly и QuantumCell.

Перевод ИИ

Текст статьи доступен на языке оригинала.

Нажмите кнопку «Перевести статью» выше, чтобы сгенерировать перевод с помощью ИИ.

Оригинальный контент

Источник

PR-Inside.com: 2026-08-27 10:25:05 STOCKHOLM, SE / ACCESS Newswire / August 27, 2026 / AlzeCure Pharma AB ("AlzeCure" or "The Company") (STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announced today that it will participate in the Pareto Securities 17th Annual Healthcare Conference on September 2, where CEO Martin Jönsson will give a company presentation and answer questions about the latest developments and AlzeCure's plans for the future. Venue: Hotel At Six, Brunkebergstorg 6, Stockholm Format: Presentation and 1×1 meetingsPresentation time: September 2, 2026, 17:05-17:25 CEST (room: Event Small) The presentation will also be available afterwards on AlzeCure's website: https://www.alzecurepharma.se/en/presentations-and-interviews/ For more information about the event, please visit Pareto's website: https://paretosec.com/updates/events-and-conferences For more information, please contact Martin Jönsson, CEOTel: +46(0)70 786 94 43 [email protected] About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish biotech company developing new, innovative drug therapies for severe diseases and conditions affecting the central nervous system, such as Alzheimer's disease and pain - indications where available treatment options today are very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several drug candidates in parallel based on three research platforms: NeuroRestore®, Alzstatin® and Painless. AlzeCure has recently signed collaboration and outlicensing agreements with Eli Lilly on the Alzstatin platform, and with QuantumCell ApS on the NeuroRestore platform. FNCA Sweden AB is the company's Certified Adviser. For more information, visit www.alzecurepharma.com Image Attachments Martin Jönsson CEO AlzeCure Pharma Attachments AlzeCure Pharma to present at the Pareto Securities 17th Annual Healthcare Conference on September 2 SOURCE: AlzeCure Pharma